“一带一路”背景下中医药产品国际化质量监管的多方博弈模型
|
摘要
"一带一路"是新时期我国扩大和深化对外开放的战略性决策,这一宏伟计划进一步加强了中国和世界各国的互利合作。"一带一路"战略的深入实施,一方面为中医药这一中国特有的医疗技术走出国门,实现国际化提供了前所未有的发展机遇;另一方面,中医药在国际化过程中也面临着诸如文化背景差异、知识产权的流失、贸易壁垒以及产品质量安全等挑战。对"一带一路"的背景下的中医药国际化过程中的医药产品质量安全问题的研究,以现有运行良好的中医药国际化模式为研究基础,充分考虑参与产品质量监管的国内企业、国外合作机构和联合监管机构的产品质量监测行为,以各方利益最大化为目标,构建了三方静态博弈模型。通过研究监测成本等因素对于三方产品质量监测行为的影响可以发现监管的成本、监管的力度以及不监管可能带来的损失对于各方是否进行产品质量监测起决定性作用。
"The Belt and Road" is a strategic decision for China to expand and deepen its opening up in the new era. This grand plan further strengthens mutually beneficial cooperation between China and the rest of the world. The in-depth implementation of the "The Belt and Road" strategy provides an unprecedented opportunity for Chinese medicine to go abroad and achieve internationalization. On the other hand, Chinese medicine is also facing many challenges in the process of internationalization, such as background differences,loss of intellectual property rights, trade barriers, and product quality and safety. The research on the quality and safety of pharmaceutical products in the process of internationalization of traditional Chinese medicine in the context of the "Belt and Road" is based on the existing well-functioning internationalization model of Chinese medicine, and fully considers domestic enterprises and foreign countries involved in product quality supervision. The product quality monitoring behavior of the cooperative institutions and the joint regulatory agencies, with the goal of maximizing the interests of all parties, constructed a three-party static game model.By studying the impact of factors such as monitoring costs on the quality monitoring behavior of tripartite products, it can be found that the cost of supervision, the intensity of supervision, and the possible losses caused by non-regulation play a decisive role in whether or not the parties conduct product quality monitoring.
"The Belt and Road" is a strategic decision for China to expand and deepen its opening up in the new era. This grand plan further strengthens mutually beneficial cooperation between China and the rest of the world. The in-depth implementation of the "The Belt and Road" strategy provides an unprecedented opportunity for Chinese medicine to go abroad and achieve internationalization. On the other hand, Chinese medicine is also facing many challenges in the process of internationalization, such as background differences,loss of intellectual property rights, trade barriers, and product quality and safety. The research on the quality and safety of pharmaceutical products in the process of internationalization of traditional Chinese medicine in the context of the "Belt and Road" is based on the existing well-functioning internationalization model of Chinese medicine, and fully considers domestic enterprises and foreign countries involved in product quality supervision. The product quality monitoring behavior of the cooperative institutions and the joint regulatory agencies, with the goal of maximizing the interests of all parties, constructed a three-party static game model.By studying the impact of factors such as monitoring costs on the quality monitoring behavior of tripartite products, it can be found that the cost of supervision, the intensity of supervision, and the possible losses caused by non-regulation play a decisive role in whether or not the parties conduct product quality monitoring.
引文
[1]崔圆月,胡凌娟,孟浩婷.“一带一路”倡议下的中医药服务贸易[J].中国医药导报,2018,15(4):108-112.
[2]孙刚.我国中医药国际化发展的SWOT分析——屠呦呦获诺贝尔奖启示[J].中国全科医学,2016,B12:417-419.
[3]王云丽.“一带一路”背景下中医药海外发展研究[J].当代经济,2018(1):10-12.
[4]张诗钰,黄建元,申俊龙,等.“一带一路”战略背景下中医药国际化区域合作的路径选择与策略优化[J].中国卫生事业管理,2017,34(3):172-176.
[5]刘峥.困境与突破:中药材供应链创新发展研究[J].中草药,2017,48(19):4126-4132.
[6]江许胜,刘峥,耿道理,等.中药材绿色供应链管理驱动力与系统模型构建——以安徽亳州中药材供应链为例[J].中药材,2017,40(5):1007-1013.
[7]齐明,王雄伟.基于“一带一路”战略的中医药国际化的机遇与挑战[J].医学与社会,2018,31(4):49-51.
(1)本文获得“2018年上海市研究生学术论坛”优秀论文三等奖。
[2]孙刚.我国中医药国际化发展的SWOT分析——屠呦呦获诺贝尔奖启示[J].中国全科医学,2016,B12:417-419.
[3]王云丽.“一带一路”背景下中医药海外发展研究[J].当代经济,2018(1):10-12.
[4]张诗钰,黄建元,申俊龙,等.“一带一路”战略背景下中医药国际化区域合作的路径选择与策略优化[J].中国卫生事业管理,2017,34(3):172-176.
[5]刘峥.困境与突破:中药材供应链创新发展研究[J].中草药,2017,48(19):4126-4132.
[6]江许胜,刘峥,耿道理,等.中药材绿色供应链管理驱动力与系统模型构建——以安徽亳州中药材供应链为例[J].中药材,2017,40(5):1007-1013.
[7]齐明,王雄伟.基于“一带一路”战略的中医药国际化的机遇与挑战[J].医学与社会,2018,31(4):49-51.
(1)本文获得“2018年上海市研究生学术论坛”优秀论文三等奖。